Murine Leukemia/Lymphoid Lymphoma models for evaluating antitumor effects of CAR-CD19-modified T cells

• Grant number: 17/09491-8
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• Start date: June 01, 2017
• End date: November 30, 2018
• Field of knowledge: Biological Sciences - Immunology - Cellular Immunology
• Principal Investigator: Dimas Tadeu Covas
• Grantee: Marcelo de Souza Fernandes Pereira
• Host Institution: Hemocentro de Ribeirão Preto. Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP (HCMRP). Secretaria da Saúde (São Paulo - Estado). Ribeirão Preto , SP, Brazil
• Associated research grant: 13/08135-2 - CTC - Center for Cell-Based Therapy, AP.CEPID

Abstract

Most of B-cell neoplasms are responsive to chemotherapy, however, in some patients this treatment shown a non-effective response presenting recurrence. Immunotherapies have been described as an alternative for cancer treatment, been a high innovative technology in which cells of the immune system can be genetically engineered with Chimeric Antigen Receptors (CAR). These cells perform a specific recognition of cancer cells independent of histocompatibility complex.Different types of CARs have been developed to recognize tumor cell specific antigens. Usually, anti-CD19 CAR-modified T cells have been successfully applied in patients with B cell neoplasms, such as Acute Lymphoblastic Leukemia (ALL) and Burkitt's Lymphoma (LB). This approach has shown promising results in clinical trials. Although several groups abroad have demonstrated the efficiency of this treatment in clinical trials, it is important to implant this therapeutic technology in Brazil, and the generation of a murine model of B-cell lymphoid neoplasia as well as, which will be really important to determining The therapeutic potential of CAR-T-CD19 cells in xenogeneic models. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

PICANCO-CASTRO, VIRGINIA; MOCO, PABLO DIEGO; MIZUKAMI, AMANDA; VAZ, LETICIA DELFINI; FERNANDES PEREIRA, MARCELO DE SOUZA; SILVESTRE, RENATA NACASAKI; COTTAS DE AZEVEDO, JULIA TEIXEIRA; BOMFIM, ALINE DE SOUSA; DE ABREU NETO, MARIO SOARES; RIBEIRO MALMEGRIM, KELEN CRISTINA; et al. Establishment of a simple and efficient platform for car-t cell generation and expansion: from lentiviral production to in vivo studies. Hematology, Transfusion and Cell Therapy, v. 42, n. 2, p. 9-pg., 2020-04-01. (12/23228-4, 17/09491-8, 16/08374-5, 13/08135-2)

PICANCO-CASTRO, VIRGINIA; MOCO, PABLO DIEGO; MIZUKAMI, AMANDA; VAZ, LETICIA DELFINI; FERNANDES PEREIRA, MARCELO DE SOUZA; SILVESTRE, RENATA NACASAKI; COTTAS DE AZEVEDO, JULIA TEIXEIRA; BOMFIM, ALINE DE SOUSA; DE ABREU NETO, MARIO SOARES; RIBEIRO MALMEGRIM, KELEN CRISTINA; et al. Establishment of a simple and efficient platform for car-t cell generation and expansion: from lentiviral production to in vivo studies. Hematology, Transfusion and Cell Therapy, v. 42, n. 2, p. 150-158, APR-JUN 2020. (17/09491-8, 16/08374-5, 13/08135-2, 12/23228-4)